Healthcare (603313) 国金证券·2025-04-27 02:05Investment Rating - The report maintains a "Buy" rating for the company [5] Core Views - The company achieved a revenue of 8.45 billion yuan in 2024, representing a year-on-year increase of 5.9%. However, it reported a net loss of 150 million yuan, a significant decline of 242.0% year-on-year, primarily due to uncertainty in recovering receivables from its largest customer, leading to a provision for bad debts of 300 million yuan [2][4] - The company experienced a mixed performance across regions, with domestic revenue growing by 3.6% to 1.48 billion yuan, while overseas revenue increased by 6.7% to 6.75 billion yuan in 2024. In Q4 2024, domestic revenue decreased by 8.5%, while overseas revenue grew by 6.2% [3] - The company's gross margin for 2024 decreased by 1.5 percentage points to 36.9%, attributed to a higher proportion of overseas OEM business and changes in product mix. The increase in sales expenses was driven by the promotion of its own brand and cross-border e-commerce operations [4] Summary by Sections Performance Overview - In 2024, the company reported a revenue of 84.5 billion yuan and a net profit of -1.5 billion yuan, with Q4 figures showing revenue of 23.2 billion yuan and a net profit of 1.56 million yuan [2] Operational Analysis - Domestic and overseas revenues for 2024 were 14.8 billion yuan and 67.5 billion yuan, respectively. The company continues to optimize its store operations and enhance its brand presence [3] - The company has 174 direct-operated stores and 848 distribution stores, with steady growth in single-store revenue [3] Profitability Forecast - The company expects EPS for 2025-2027 to be 0.46, 0.63, and 0.80 yuan, respectively, with corresponding PE ratios of 15, 11, and 8 times [5] Financial Projections - Revenue is projected to grow to 93.77 billion yuan in 2025, with a net profit forecasted to recover to 262 million yuan [10]